- Record: found
- Abstract: not found
- Article: not found
Phase 1 Study of OPT-302 inhibition of Vascular Endothelial Growth Factors C and D for Neovascular Age-Related Macular Degeneration
Pravin U. Dugel ,
David S. Boyer ,
Andrew N. Antoszyk ,
Nathan C. Steinle ,
Michael P. Varenhorst ,
Joel A. Pearlman ,
Mark C. Gillies ,
Robert P. Finger ,
Megan E. Baldwin ,
Ian M. Leitch
October 2019
October 2019
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
<p class="first" id="d9622214e198">OPT-302 is a novel inhibitor of vascular endothelial
growth factor (VEGF)-C and VEGF-D.
A phase 1 trial assessed the safety of intravitreal OPT-302 as monotherapy or combined
with ranibizumab (Lucentis; Genentech, South San Francisco, CA) in patients with neovascular
age-related macular degeneration (nAMD).
</p>